0001209191-19-056042.txt : 20191112 0001209191-19-056042.hdr.sgml : 20191112 20191112163930 ACCESSION NUMBER: 0001209191-19-056042 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20191112 FILED AS OF DATE: 20191112 DATE AS OF CHANGE: 20191112 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Novak Alfred J CENTRAL INDEX KEY: 0001388862 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-38135 FILM NUMBER: 191210211 MAIL ADDRESS: STREET 1: 325 NE 6TH ST CITY: BOCA RATON STATE: FL ZIP: 33432 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Dova Pharmaceuticals Inc. CENTRAL INDEX KEY: 0001685071 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 813858961 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 240 LEIGH FARM ROAD CITY: DURHAM STATE: NC ZIP: 27707 BUSINESS PHONE: 919-806-4487 MAIL ADDRESS: STREET 1: 240 LEIGH FARM ROAD CITY: DURHAM STATE: NC ZIP: 27707 FORMER COMPANY: FORMER CONFORMED NAME: Dova Pharmaceuticals, Inc. DATE OF NAME CHANGE: 20160919 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2019-11-12 1 0001685071 Dova Pharmaceuticals Inc. DOVA 0001388862 Novak Alfred J C/O DOVA PHARMACEUTICALS, INC. 240 LEIGH FARM ROAD, SUITE 245 DURHAM NC 27707 1 0 0 0 Common Stock 2019-11-12 4 D 0 6901 D 0 D Stock Option (Right to Buy) 7.32 2019-11-12 4 D 0 33000 D 2027-05-24 Common Stock 33000 0 D Stock Option (Right to Buy) 9.36 2019-11-12 4 D 0 10000 D 2029-04-25 Common Stock 10000 0 D Disposed pursuant to an agreement and plan of merger by and between the Issuer, Swedish Orphan Biovitrum AB and Dragonfly Acquisition Corp. (the "Merger") in exchange for $27.50 per share of Issuer's common stock including any shares subject to each restricted stock unit on the effective date of the Merger, plus (ii) one non-transferable contingent value right per share, which represents the right to receive $1.50, without interest and subject to any withholding taxes, upon the achievement of a specified milestone. This option, which provided for vesting over a period of three years as follows: (i) one-third of the total shares subject to the option shall vest on May 25, 2018, and (ii) 1/36th of total shares subject to the option shall vest monthly thereafter over the remaining two years of the vesting period, was accelerated and canceled in the Merger in exchange for a cash payment of 665,940.00, representing the difference between the exercise price of outstanding shares subject to the option and the market value of the underlying common stock on the effective date of the Merger ($27.50 per share). In addition, one non-transferable contingent value right per share, which represents the right to receive $1.50, without interest and subject to any withholding taxes, upon the achievement of a specified milestone was awarded to the Reporting Person for each outstanding share subject to the option. This option, which provided for vesting monthly over one year from the grant date and in any event will be fully vested on the date of the next annual meeting of our stockholders, was accelerated and canceled in the Merger in exchange for a cash payment of $181,400.00, representing the difference between the exercise price of outstanding shares subject to the option and the market value of the underlying common stock on the effective date of the Merger ($27.50 per share). In addition, one non-transferable contingent value right per share, which represents the right to receive $1.50, without interest and subject to any withholding taxes, upon the achievement of a specified milestone was awarded to the Reporting Person for each outstanding share subject to the option. /s/ Mark Ballantyne, Attorney-in-Fact 2019-11-12